Adalimumab plus moderate steroid for difficult Behçet’s eye inflammation
Part of Eyes & vision clinical trials.
This trial studies whether adalimumab (an immune medicine) added to a medium-dose steroid improves eye inflammation from refractory Behçet’s disease that keeps coming back. It also checks safety to see if the benefits outweigh risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Behçet’s disease and have had recent eye inflammation in the front or back of the eye (uveitis).
- Your eye inflammation has returned despite treatment, meaning it is considered refractory.
- You are currently taking at least 10 mg per day of prednisone (or an equivalent steroid dose).
- You have not used a TNF-alpha inhibitor (a type of immune drug like adalimumab or similar) in the last 3 months.
- You are not pregnant or breastfeeding.
- You do not have serious infections or positive tests for TB (T-SPOT), hepatitis B, hepatitis C, HIV, or syphilis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two forms of the same medicine (adalimumab) to treat non-infectious uveitis, an inflammation inside the eye. It aims to see which delivery method works better to control active inflammation and protect vision.
This study tests whether a lower dose of adalimumab (a biologic medication) can keep controlling chronic non-infectious uveitis (eye inflammation that is not caused by an infection) after it has been well-controlled for a long time. If you have stable eye inflammation and have been on the standard adalimumab dose (40 mg every 2 weeks) for at least 24 weeks, this trial may be suitable for you.
This study tests a new drug (GenSci048) for people with active, non-infectious uveitis in the middle or back of the eye, who are already taking oral steroids. The goal is to see if the drug can better control inflammation and reduce the need for steroids.
This study compares two medicines—adalimumab and tocilizumab—to see which works better and is safer for severe “uveitis” in people with Behçet’s disease. It’s meant for adults whose eye inflammation threatens their sight.
This trial tests a combination of two medications (adalimumab and mycophenolate mofetil) to reduce eye inflammation in people with uveitis that requires steroids. It aims to help patients use less steroid medication while keeping their uveitis under control.
This study tests an injection called adalimumab (Tebiovio®) to see if it helps control inflammation in the eyes of adults with non-infectious uveitis. It might be a good option if you are already on steroid pills and looking for another treatment.
Hear when a new Uveitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.